IL10 and melanoma: In a melanoma study, Sun et al. reported that CD8+ TILs present in tumor site upregulate IL-10R and PD-1, and that PBMCs of melanoma patients produce IL-10, which limits the proliferation and survival of IL10R+ tumor antigen-specific CD8+ T cells [23].